You are here

Share:

NSAIDs that Assist the Treatment of Human Diseases

Summary
Researchers at the National Cancer Institute (NCI) developed compounds containing both a non-steroidal anti-inflammatory drug (NSAID) and a nitroxyl (HNO) -releasing agent that have significantly reduced toxicity, allowing their use for extended periods of time without severe side effects.The HNO-releasing moiety contained in this invention may expand the medical utility of NSAIDs. HNO releasing agents possess anticancer activity as well as good antioxidant properties, which has potential benefit for a variety of human diseases, including acute and chronic inflammation. NCI seeks parties to license or co-develop this technology.
NIH Reference Number
E-131-2011
Product Type
Keywords
  • Nitroxyl, HNO, nitric oxide, non-steroidal anti-inflammatory drugs, NSAID, inflammation
  • David Wink
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Non-steroidal anti-inflammatory drugs (NSAIDs) have long been used to treat a variety of inflammatory conditions.  Many of these conditions, such as cancer or arthritis, require long term use of the NSAIDs due to the chronic nature of the disease.  However, the NSAIDs in current use have toxicities associated with their long-term use that hinder their use for these chronic conditions.    

Researchers at the NCI, in collaboration with Wake Forest University, have developed novel hybrid compounds which combine a NSAID with a nitroxyl (HNO) releasing agent. These modified NSAIDs have significantly reduced toxicity compared to the conventionally used NSAIDs which may allow their administration for the extended periods needed for more chronic conditions without severe side effects.  The adverse side effects (i.e. heart attack, thrombosis and severe gut toxicity) observed with conventional NSAIDs are well documented.  In fact, some of these drugs (i.e. Vioxx) were withdrawn from the market as a result of these adverse events. The compounds of the invention may alleviate these problems due to their lower toxicity. The HNO releasing moiety contained in the invention may expand the medical utility of NSAIDs. HNO releasing agents possess anticancer activity as well as good antioxidant properties, which has potential benefit for a variety of human diseases, including acute and chronic inflammation. 

Potential Commercial Applications
  • Therapeutic for the treatment of inflammatory diseases 
  • Preventative drug for cardiovascular disease, diabetes and cancer 
Competitive Advantages
  • Reduced toxicity compared to conventionally used NSAIDs

 

Inventor(s)

Dave Wink (NCI), Wilmarie Flores-Santana, S. Bruce King, Murali Krishna Cherukuri (NCI), James Mitchell (NCI)

Development Stage
Publications

W. Flores-Santana et al. [PMID 21658022]

Patent Status
  • U.S. Patent Issued: U.S. Patent Number 9012647, Issued 21 Apr 2015
Therapeutic Area
Updated
Wednesday, February 21, 2018